



**For Immediate Release**  
September 22, 2006

Media Contact:  
Maria Cantor  
(617) 768-6690

**Genzyme Announces Thyrogen<sup>®</sup> Added to Medicare's  
Competitive Acquisition Program (CAP)**

CAMBRIDGE, Mass. – Genzyme Corporation today announced that Thyrogen<sup>®</sup> (thyrotropin alfa for injection) has been added to the list of drugs available under the Medicare Part B Competitive Acquisition Program (CAP). This will allow Thyrogen, a diagnostic tool used to detect recurring or remaining thyroid cancer cells in patients with well-differentiated thyroid cancer, to now be ordered for Medicare-covered patients through BioScrip, the approved CAP vendor. As a result of the inclusion of Thyrogen on the list of approved CAP drugs, physicians electing to participate in the program will no longer have to buy and bill Thyrogen under the average sales price (ASP) system, but instead will be able to obtain Thyrogen directly through BioScrip.

The CAP is expected to benefit participating physicians by reducing their time and the time of their office staff in completing and submitting paperwork. Under CAP, the physician does not purchase the drug and seek payment from Medicare but, rather, orders the medication from Bioscrip. Physicians who choose to participate in the CAP continue to be paid by Medicare for the cost of administering the drugs to Medicare beneficiaries. BioScrip's team of specialists handle the billing for drugs included in the

(more)

CAP and collect any deductible and coinsurance from beneficiaries. Physicians can also choose to continue to purchase drugs directly in the market and be paid at the statutorily established rate, which, for most Medicare drugs, is 106% of Average Sales Price (ASP).

Thyrogen is currently indicated in the U.S. for use as a diagnostic tool in the management of patients being tested for the recurrence of well-differentiated thyroid cancer. The product allows patients to avoid the potentially debilitating symptoms associated with thyroid hormone withdrawal.

#### How to Enroll in CAP

Physicians can enroll in the CAP program by completing the Physician Election Agreement which can be downloaded from the CMS website at [www.cms.hhs.gov/CompetitiveAcquisforBios/](http://www.cms.hhs.gov/CompetitiveAcquisforBios/), from the Bioscrip website at [www.bioscrip.com](http://www.bioscrip.com) or by contacting Bioscrip at (866) 366-7915. The open enrollment period for 2007 begins October 1st and ends November 15, 2006.

For a copy of the Election Agreement, please visit [www.cms.hhs.gov/CompetitiveAcquisforBios/](http://www.cms.hhs.gov/CompetitiveAcquisforBios/), [www.bioscrip.com](http://www.bioscrip.com) or contact Bioscrip at (866) 366-7915. Completed forms must be returned to the Local Medicare Carrier. The participating CAP physician election agreement must be postmarked no later than November 15, 2006 for participation in the program beginning January 1, 2007. Local Medicare Carrier contact information can be found on the CMS website at [www.cms.hhs.gov/CompetitiveAcquisforBios/](http://www.cms.hhs.gov/CompetitiveAcquisforBios/).

#### Background Information on Thyrogen

Thyrogen was initially approved for marketing in the United States in November, 1998 for use in patients with well-differentiated thyroid cancer who have had their

(more)

thyroid gland removed as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging. These patients must take thyroid hormone suppression therapy (THST) and undergo periodic testing to facilitate the early detection of recurrent disease. Thyrogen allows patients to remain on their THST and avoid the debilitating symptoms of clinical hypothyroidism during TSH stimulated follow-up testing. For patients who may be undergoing follow-up testing with a serum thyroglobulin test without being withdrawn from their thyroid hormone suppression therapy, Thyrogen offers significantly improved sensitivity for detection of recurrent or metastatic cancer. Thyrogen has been on the market in Europe since 2001 and in the U.S. since 1998.

Thyrogen is injected in a muscle, and is available only by prescription. The most common side effects reported in clinical studies were nausea, headache, weakness & vomiting. When using Thyrogen, there is a risk that thyroid cancer cells may not be detected and diagnosis of recurring cancer may be missed.

### About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. This year marks the 25<sup>th</sup> anniversary of Genzyme's founding. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 8,500 employees in locations spanning the globe and 2005 revenues of \$2.7 billion. Genzyme has been selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.

With many established products and services helping patients in more than 80 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on

(more)

rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune diseases, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as heart disease and other areas of unmet medical need.

Genzyme<sup>®</sup> and Thyrogen<sup>®</sup> are registered trademarks of Genzyme Corporation. All rights reserved.

# # #

Genzyme's press releases and other company information are available at [www.genzyme.com](http://www.genzyme.com) and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-703-797-1866 outside the United States.